search
Back to results

BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT Study (BACCARAT)

Primary Purpose

Breast Cancer, Cardiac Toxicity

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Subclinical cardiac lesions and biomarkers
Sponsored by
Sophie JACOB
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Breast Cancer focused on measuring Radiotherapy, Echocardiography, Strain strain rate, Coronary computed tomography angiography, Segments of coronary arteries, Subclinical functional and anatomical cardiac lesions, Biomarkers, Heart dosimetry

Eligibility Criteria

50 Years - 70 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Age between 50 and 70 years
  • Women surgically treated for left or right breast cancer and for whom adjuvant treatment is radiotherapy with irradiation of the breast or chest wall irradiation and possibly ganglion chains,
  • Adjuvant radiotherapy with 3DCRT performed in Clinique Pasteur Toulouse
  • WHO performance status ECOG - Eastern Cooperative Oncology Group (index normally used to describe the patient's condition) = 0 or 1
  • Being volunteer to participate in the study and have signed the consent form

Exclusion Criteria:

  • Indication of adjuvant chemotherapy
  • Clinically or radiologically detectable metastasis
  • Personal history of coronary artery disease or myocardial disease
  • Personal history of breast cancer or other cancer requiring radiotherapy to the thorax
  • Patient with controlled infection or severe disease and / or non-hazardous to their participation in the study
  • Contraindications to injection of iodinated contrast (for CCTA): pregnancy, renal failure, allergy.
  • Pregnancy, lactation
  • Abnormal echocardiography before radiotherapy:
  • LVEF <50%
  • Longitudinal strain> - 16%
  • Longitudinal strain rate <1% / s
  • Abnormal wall motion
  • CCTA before radiotherapy showing that therapeutic management is required (coronary-artery calcium (CAC) score>600)

Sites / Locations

  • Clinique PasteurRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Breast cancer patients with 3DCRT

Arm Description

Measures of subclinical functional and anatomical cardiac lesions and circulating biomarkers 'Subclinical cardiac lesions and biomarkers'

Outcomes

Primary Outcome Measures

Number of patients with decreased myocardial function assessed by echocardiography
Number of patients with a decrease in the mean strain or strain rate measured from the echocardiography of the order of 5% between the measurement before RT and 24 months after RT
Number of patients with increased coronary plaques assessed by CT coronary angiography
Number of patients with an increase of the average index of coronary plaques measured from the CT coronary angiography in the order of 15% between the measurements before RT and 24 months after RT

Secondary Outcome Measures

Decrease in the strain or strain rate
Modification in series of circulating biomarkers of cardiac lesions
Classical biomarkers of cardiac injury: C-reactive protein, Troponin I, B-type natriuretic peptide (NT-Pro BNP), beta2-Microglobulin, Galectin 3 / Inflammatory cytokines: Interleukin 6, Interleukin 8, Interleukin 18, TNF-α / Endothelial activation and dysfunction: sVCAM,-1 , s-ICAM-1, E-selectin, P-selectin , vWF, PAI-1, Fibrinogen , Thrombomodulin, TGF-β1 / Microparticles: CD14, CD31, CD41, CD3, CD235a / microRNAs : miR-1, miR-133, miR-208, miR-499, miR-126, miR-130, miR-145, miR-181, miR-150, miR-155, miR-223, miR-17, miR-18, miR-22, miR-34, miR-92, miR-140, miR-182, miR-199, miR-423, miR-590
Correlation between the absorbed radiation dose by the whole heart and different structures of the heart and measurements of strain and strain rate and indices of coronary plaques

Full Information

First Posted
November 6, 2015
Last Updated
June 18, 2018
Sponsor
Sophie JACOB
Collaborators
Institut de Radioprotection et de Surete Nucleaire, Clinique Pasteur, Institut National de la Santé Et de la Recherche Médicale, France
search

1. Study Identification

Unique Protocol Identification Number
NCT02605512
Brief Title
BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT Study
Acronym
BACCARAT
Official Title
Early Detection and Prediction of Cardiotoxicity in Radiotherapy-treated Breast Cancer Patients
Study Type
Interventional

2. Study Status

Record Verification Date
June 2018
Overall Recruitment Status
Unknown status
Study Start Date
October 2015 (undefined)
Primary Completion Date
September 2019 (Anticipated)
Study Completion Date
September 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Sophie JACOB
Collaborators
Institut de Radioprotection et de Surete Nucleaire, Clinique Pasteur, Institut National de la Santé Et de la Recherche Médicale, France

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Breast radiotherapy RT used until the 1990s was clearly responsible for increased mortality due to long term cardiac complications. Since the 2000s, improvements have appeared in dose distributions to organ at risks such as heart, but now, little is known on the risk of potential cardiac impairment in this population, in particular for chemotherapy naive patients. Based on the state that clinically detectable cardiotoxicity is generally preceded by subclinical cardiac dysfunctions, the aim of the BACCARAT study (BreAst Cancer and Cardiotoxicity induced by RAdioTherapy) is to evaluate whether adjuvant 3DCRT induces cardiac toxicity that could be detected in the first two years after treatment based on a global approach with repeated analysis of subclinical functional and anatomical cardiac lesions in myocardial and coronary levels and circulating biomarkers.
Detailed Description
BACCARAT study consists in a monocentric prospective cohort study that will finally include 120 women treated with adjuvant RT for breast cancer in the Clinique Pasteur in Toulouse, and followed for 2 years after RT. Women aged 50 to 70 years, treated for breast cancer and for whom adjuvant 3DCRT is indicated, without chemotherapy are eligible for the study. Baseline and follow-up include measures of functional myocardial dysfunction based on 2D-speckle tracking echocardiography, anatomical coronary lesions based on Coronary computed tomography angiography, and a wide panel of circulating biomarkers. Absorbed doses is evaluated for whole heart and for each different parts of heart, in particular coronary arteries. Analysis on occurrence and evolutions of subclinical cardiac lesions and biomarkers will be performed and completed with dose-response relations with absorbed doses of different heart segments.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer, Cardiac Toxicity
Keywords
Radiotherapy, Echocardiography, Strain strain rate, Coronary computed tomography angiography, Segments of coronary arteries, Subclinical functional and anatomical cardiac lesions, Biomarkers, Heart dosimetry

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Breast cancer patients with 3DCRT
Arm Type
Other
Arm Description
Measures of subclinical functional and anatomical cardiac lesions and circulating biomarkers 'Subclinical cardiac lesions and biomarkers'
Intervention Type
Other
Intervention Name(s)
Subclinical cardiac lesions and biomarkers
Intervention Description
Functional myocardial dysfunction based on 2D-speckle tracking echocardiography, Anatomical coronary lesions based on Coronary computed tomography angiography, a panel of circulating biomarkers based on blood samples and plasma
Primary Outcome Measure Information:
Title
Number of patients with decreased myocardial function assessed by echocardiography
Description
Number of patients with a decrease in the mean strain or strain rate measured from the echocardiography of the order of 5% between the measurement before RT and 24 months after RT
Time Frame
2 years after 3DCRT (baseline measures performed before radiotherapy)
Title
Number of patients with increased coronary plaques assessed by CT coronary angiography
Description
Number of patients with an increase of the average index of coronary plaques measured from the CT coronary angiography in the order of 15% between the measurements before RT and 24 months after RT
Time Frame
2 years after 3DCRT (baseline measures performed before radiotherapy)
Secondary Outcome Measure Information:
Title
Decrease in the strain or strain rate
Time Frame
6 months after 3DCRTand 2 years after 3DCRT (baseline measures performed before radiotherapy)
Title
Modification in series of circulating biomarkers of cardiac lesions
Description
Classical biomarkers of cardiac injury: C-reactive protein, Troponin I, B-type natriuretic peptide (NT-Pro BNP), beta2-Microglobulin, Galectin 3 / Inflammatory cytokines: Interleukin 6, Interleukin 8, Interleukin 18, TNF-α / Endothelial activation and dysfunction: sVCAM,-1 , s-ICAM-1, E-selectin, P-selectin , vWF, PAI-1, Fibrinogen , Thrombomodulin, TGF-β1 / Microparticles: CD14, CD31, CD41, CD3, CD235a / microRNAs : miR-1, miR-133, miR-208, miR-499, miR-126, miR-130, miR-145, miR-181, miR-150, miR-155, miR-223, miR-17, miR-18, miR-22, miR-34, miR-92, miR-140, miR-182, miR-199, miR-423, miR-590
Time Frame
5 weeks after initiation of 3DCRT (corresponding to the end of 3DCRT sessions), 6 months after 3DCRTand 2 years after 3DCRT (baseline measures performed before radiotherapy)
Title
Correlation between the absorbed radiation dose by the whole heart and different structures of the heart and measurements of strain and strain rate and indices of coronary plaques
Time Frame
2 years

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age between 50 and 70 years Women surgically treated for left or right breast cancer and for whom adjuvant treatment is radiotherapy with irradiation of the breast or chest wall irradiation and possibly ganglion chains, Adjuvant radiotherapy with 3DCRT performed in Clinique Pasteur Toulouse WHO performance status ECOG - Eastern Cooperative Oncology Group (index normally used to describe the patient's condition) = 0 or 1 Being volunteer to participate in the study and have signed the consent form Exclusion Criteria: Indication of adjuvant chemotherapy Clinically or radiologically detectable metastasis Personal history of coronary artery disease or myocardial disease Personal history of breast cancer or other cancer requiring radiotherapy to the thorax Patient with controlled infection or severe disease and / or non-hazardous to their participation in the study Contraindications to injection of iodinated contrast (for CCTA): pregnancy, renal failure, allergy. Pregnancy, lactation Abnormal echocardiography before radiotherapy: LVEF <50% Longitudinal strain> - 16% Longitudinal strain rate <1% / s Abnormal wall motion CCTA before radiotherapy showing that therapeutic management is required (coronary-artery calcium (CAC) score>600)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sophie Jacob, PhD
Phone
+33630704719
Email
sophie.jacob@irsn.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Atul Pathak, MD PhD
Organizational Affiliation
Clinique Pasteur Toulouse
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinique Pasteur
City
Toulouse
ZIP/Postal Code
31300
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Atul Pathak, MD PhD
Email
apathak@clinique-pasteur.com

12. IPD Sharing Statement

Citations:
PubMed Identifier
32819449
Citation
Walker V, Lairez O, Fondard O, Jimenez G, Camilleri J, Panh L, Broggio D, Bernier MO, Laurier D, Ferrieres J, Jacob S. Myocardial deformation after radiotherapy: a layer-specific and territorial longitudinal strain analysis in a cohort of left-sided breast cancer patients (BACCARAT study). Radiat Oncol. 2020 Aug 20;15(1):201. doi: 10.1186/s13014-020-01635-y.
Results Reference
derived
PubMed Identifier
31727075
Citation
Walker V, Lairez O, Fondard O, Pathak A, Pinel B, Chevelle C, Franck D, Jimenez G, Camilleri J, Panh L, Broggio D, Derreumaux S, Bernier MO, Laurier D, Ferrieres J, Jacob S. Early detection of subclinical left ventricular dysfunction after breast cancer radiation therapy using speckle-tracking echocardiography: association between cardiac exposure and longitudinal strain reduction (BACCARAT study). Radiat Oncol. 2019 Nov 14;14(1):204. doi: 10.1186/s13014-019-1408-8.
Results Reference
derived
PubMed Identifier
30732640
Citation
Jacob S, Camilleri J, Derreumaux S, Walker V, Lairez O, Lapeyre M, Bruguiere E, Pathak A, Bernier MO, Laurier D, Ferrieres J, Gallocher O, Latorzeff I, Pinel B, Franck D, Chevelle C, Jimenez G, Broggio D. Is mean heart dose a relevant surrogate parameter of left ventricle and coronary arteries exposure during breast cancer radiotherapy: a dosimetric evaluation based on individually-determined radiation dose (BACCARAT study). Radiat Oncol. 2019 Feb 7;14(1):29. doi: 10.1186/s13014-019-1234-z.
Results Reference
derived
PubMed Identifier
27056179
Citation
Jacob S, Pathak A, Franck D, Latorzeff I, Jimenez G, Fondard O, Lapeyre M, Colombier D, Bruguiere E, Lairez O, Fontenel B, Milliat F, Tamarat R, Broggio D, Derreumaux S, Ducassou M, Ferrieres J, Laurier D, Benderitter M, Bernier MO. Early detection and prediction of cardiotoxicity after radiation therapy for breast cancer: the BACCARAT prospective cohort study. Radiat Oncol. 2016 Apr 7;11:54. doi: 10.1186/s13014-016-0627-5.
Results Reference
derived

Learn more about this trial

BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT Study

We'll reach out to this number within 24 hrs